SEC Filing Summary: Coeptis Therapeutics Holdings, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Coeptis Therapeutics Holdings, Inc. (not Z Squared Inc.) on February 9, 2026. The report covers corporate governance events and regulatory compliance status updates occurring in early February 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation adjustments and regulatory compliance.
Material Changes and Corporate Actions
- Option Repricing and Exchange Program: On February 11, 2026, the Company implemented a program allowing holders of options with exercise prices above the current fair market value to either reprice options or exchange them for restricted stock.
- Accelerated Vesting: All outstanding options, including those out-of-the-money, were accelerated to full vesting.
- Specific Transactions:
- Option-to-Stock Exchange: Nine officers and directors surrendered options totaling 109,000 shares in exchange for an equivalent number of restricted shares.
- Option Exercises: The same nine individuals exercised retained options for a total of 193,350 shares of restricted common stock.
- Regulatory Compliance: The Company previously received notice of non-compliance with Nasdaq Listing Rules regarding the failure to hold an annual meeting within 12 months of the fiscal year-end (December 31, 2024). On February 9, 2026, Nasdaq confirmed the Company has regained compliance, and the matter is closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of new risks. The primary risk addressed was the potential delisting due to missed annual meeting requirements, which has been resolved.
Investor Verification Checklist
- Verify the exact number of shares issued via the option exchange and exercise programs to assess potential dilution.
- Confirm the current fair market value of the stock at the time of the repricing to understand the magnitude of the adjustment.
- Review the full text of the Option/Exchange Agreements (to be filed as an exhibit) for specific terms and conditions.
- Monitor future filings for the Company's financial performance, as this 8-K contains no financial data.